Endothelium dependent expression and underlying mechanisms of des-Arg(9)-bradykinin-induced B1R-mediated vasoconstriction in rat portal vein


Autoria(s): Basei, Fernanda L.; Cabrini, Daniela A.; Figueiredo, Claudia P.; Forner, Stefania; Hara, Daniela B.; Nascimento, Andrey F. Z.; Ceravolo, Graziela Scalianti; Carvalho, Maria Helena Catelli de; Bader, Michael; Medeiros, Rodrigo; Calixto, João Batista
Contribuinte(s)

UNIVERSIDADE DE SÃO PAULO

Data(s)

30/10/2013

30/10/2013

02/08/2013

Resumo

Endothelial dysfunction has been implicated in portal vein obstruction, a condition responsible for major complications in chronic portal hypertension. Increased vascular tone due to disruption of endothelial function has been associated with an imbalance in the equilibrium between endothelium-derived relaxing and contracting factors. Herein, we assessed underlying mechanisms by which expression of bradykinin B-1 receptor (B1R) is induced in the endothelium and how its stimulation triggers vasoconstriction in the rat portal vein. Prolonged in vitro incubation of portal vein resulted in time- and endothelium-dependent expression of B1R and cyclooxygenase-2 (COX-2). Inhibition of protein kinase C (PKC) or phosphatidylinositol 3-kinase (PI3K) significantly reduced expression of B1R through the regulation of transcription factors, activator protein-1 (AP-1) and cAMP response element-binding protein (CREB). Moreover, pharmacological studies showed that B1R-mediated portal vein contraction was reduced by COX-2, but not COX-1, inhibitors. Notably, activation of endothelial B1R increased phospholipase A(2)/COX-2-derived thromboxane A(2) (TXA(2)) levels, which in turn mediated portal vein contraction through binding to TXA(2) receptors expressed in vascular smooth muscle cells. These results provide novel molecular mechanisms involved in the regulation of B1R expression and identify a critical role for the endothelial B1R in the modulation of portal vein vascular tone. Our study suggests a potential role for B1R antagonists as therapeutic tools for diseases where portal hypertension may be involved. (C) 2012 Elsevier Inc. All rights reserved.

Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq), Brazil

Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq), Brazil

Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES), Brazil

Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES), Brazil

Programa de Apoio aos Nucleos de Excelencia (PRONEX), Brazil

Programa de Apoio aos Nucleos de Excelencia (PRONEX), Brazil

Fundacao de Apoio a Pesquisa do Estado de Santa Catarina (FAPESC), Brazil

Fundacao de Apoio a Pesquisa do Estado de Santa Catarina (FAPESC), Brazil

Identificador

PEPTIDES, NEW YORK, v. 37, n. 2, supl. 1, Part 3, pp. 216-224, OCT, 2012

0196-9781

http://www.producao.usp.br/handle/BDPI/36695

10.1016/j.peptides.2012.07.020

http://dx.doi.org/10.1016/j.peptides.2012.07.020

Idioma(s)

eng

Publicador

ELSEVIER SCIENCE INC

NEW YORK

Relação

PEPTIDES

Direitos

closedAccess

Copyright ELSEVIER SCIENCE INC

Palavras-Chave #BRADYKININ B-1 RECEPTOR #HUMAN UMBILICAL VEIN #UP-REGULATION #KININ RECEPTORS #PHARMACOLOGICAL EVIDENCE #DYSFUNCTION #AORTA #CONTRACTIONS #CELLS #INVOLVEMENT #BIOCHEMISTRY & MOLECULAR BIOLOGY #PHARMACOLOGY & PHARMACY
Tipo

article

original article

publishedVersion